Revolution Medicines, Inc.
RVMD
$99.00
$4.144.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 12.36% | 1,272.51% | |||
| Gross Profit | -12.36% | -1,272.51% | |||
| SG&A Expenses | 26.38% | 30.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.70% | 19.10% | |||
| Operating Income | -14.70% | -19.10% | |||
| Income Before Tax | -19.56% | -23.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.56% | -23.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.56% | -23.17% | |||
| EBIT | -14.70% | -19.10% | |||
| EBITDA | -14.73% | -19.15% | |||
| EPS Basic | -15.04% | -22.76% | |||
| Normalized Basic EPS | -15.04% | -22.75% | |||
| EPS Diluted | -15.04% | -22.76% | |||
| Normalized Diluted EPS | -15.04% | -22.75% | |||
| Average Basic Shares Outstanding | 3.93% | 0.34% | |||
| Average Diluted Shares Outstanding | 3.93% | 0.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||